Neuraminidase of 2007-2008 influenza A(H1N1) viruses shows increased affinity for sialic acids due to the D344N substitution

Antiviral Therapy

Volumn 16, Issue 4, 2011, Pages 597-603

  Rameix Welti, Marie Anne ^a,b,c   Munier, Sandie ^a,b,c   Le Gal, Sebastien ^a,b,c,d   Cuvelier, Frederique ^a,b,c,d   Agou, Fabrice ^e   Enouf, Vincent ^a,b,c,d   Naffakh, Nadia ^a,b,c   Van Der Werf, Sylvie ^a,b,c,d  

^a Sorbonne Paris Cité   (France)

^b CNRS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Centre National de Reference des Virus Influenza Région Nord   (France)

^e INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VIRUS HEMAGGLUTININ; SIALIC ACID; VIRUS SIALIDASE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; ENZYME ASSAY; ENZYME BINDING; ENZYME INHIBITION; ENZYME SUBSTRATE; ENZYME SUBSTRATE COMPLEX; INFLUENZA VIRUS A H1N1; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CARBOHYDRATE INTERACTION; SITE DIRECTED MUTAGENESIS; TRANSIENT EXPRESSION; VIRUS EXPRESSION; WILD TYPE;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; NEURAMINIDASE; OSELTAMIVIR; SIALIC ACIDS; VIRUS REPLICATION;

EID: 79959437028     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1804     Document Type: Article

References (22)

1. Burch J, Corbett M, Stock C, et al. Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis. Lancet Infect Dis 2009; 9:537-545.
2. Aoki FY, Boivin G, Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther 2007; 12:603-616. (Pubitemid 47235503)
3. Monto AS, McKimm-Breschkin JL, Macken C, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006; 50:2395-2402. (Pubitemid 43993177)
4. Sheu TG, Deyde VM, Okomo-Adhiambo M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008; 52:3284-3292.
5. Meijer A, Lackenby A, Hungnes O, et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis 2009; 15:552-560.
6. Dharan NJ, Gubareva LV, Meyer JJ, et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009; 301:1034-1041.
7. Hurt AC, Ernest J, Deng YM, et al. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res 2009; 83:90-93.
8. Kramarz P, Monnet D, Nicoll A, Yilmaz C, Ciancio B. Use of oseltamivir in 12 European countries between 2002 and 2007-lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses. Euro Surveill 2009; 14:19112.
9. Rameix-Welti MA, Enouf V, Cuvelier F, Jeannin P, van der Werf S. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog 2008; 4:e1000103.
10. Baz M, Abed Y, Simon P, Hamelin ME, Boivin G. Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses. J Infect Dis 2010; 201:740-745.
11. Rameix-Welti MA, Tomoiu A, Dos Santos Afonso E, van der Werf S, Naffakh N. Avian Influenza A virus polymerase association with nucleoprotein, but not polymerase assembly, is impaired in human cells during the course of infection. J Virol 2009; 83:1320-1331.
12. Rameix-Welti MA, Agou F, Buchy P, et al. Natural variation can significantly alter sensitivity to oseltamivir of Influenza A(H5N1) viruses. Antimicrob Agents Chemother 2006; 50:3809-3815. (Pubitemid 44684897)
13. Wang MZ, Tai CY, Mendel DB. Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir. Antimicrob Agents Chemother 2002; 46:3809-3816. (Pubitemid 35403254)
14. Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 2010; 328:1272-1275.
15. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 2001; 183:523-531. (Pubitemid 32147507)
16. Xu X, Zhu X, Dwek RA, Stevens J, Wilson IA. Structural characterization of the 1918 influenza virus H1N1 neuraminidase. J Virol 2008; 82:10493-10501.
17. Dominiak PM, Volkov A, Dominiak AP, Jarzembska KN, Coppens P. Combining crystallographic information and an aspherical-atom data bank in the evaluation of the electrostatic interaction energy in an enzyme-substrate complex: influenza neuraminidase inhibition. Acta Crystallogr D Biol Crystallogr 2009; 65:485-499.
18. Collins PJ, Haire LF, Lin YP, et al. Structural basis for oseltamivir resistance of influenza viruses. Vaccine 2009; 27:6317-6323.
19. Matrosovich M, Matrosovich T, Carr J, Roberts NA, Klenk HD. Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol 2003; 77:8418-8425. (Pubitemid 36871470)
20. Nelson MI, Simonsen L, Viboud C, Miller MA, Holmes EC. The origin and global emergence of adamantane resistant A/ H3N2 influenza viruses. Virology 2009; 388:270-278.
21. World Health Organization. Oseltamivir-resistant pandemic (H1N1) 2009 influenza virus, October 2009. Wkly Epidemiol Rec 2009; 84:453-459.
22. Colman PM, Varghese JN, Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 1983; 303:41-44. (Pubitemid 13125071)